Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Stockholders Equity of $24.88 million for the year ending 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +8.9% in Stockholders Equity from 2024 to 2025.
- This data is from CUMBERLAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $81.51 million | Q3 2011: $83.55 million | Q1 2012: $81.95 million | Q2 2012: $83.32 million | Q3 2012: $83.45 million | Q1 2013: $85.17 million | Q2 2013: $83.03 million | Q3 2013: $81.10 million | Q1 2014: $79.15 million | Q2 2014: $80.93 million | Q3 2014: $81.10 million | Q1 2015: $79.37 million | Q2 2015: $78.74 million | Q3 2015: $77.59 million | Q1 2016: $75.40 million | Q2 2016: $74.47 million | Q3 2016: $74.53 million | Q1 2017: $72.36 million | Q2 2017: $66.66 million | Q3 2017: $65.10 million | Q1 2018: $61.09 million | Q2 2018: $59.91 million | Q3 2018: $58.20 million | Q1 2019: $55.43 million | Q2 2019: $54.06 million | Q3 2019: $51.73 million | Q1 2020: $49.89 million | Q2 2020: $48.48 million | Q3 2020: $47.93 million | Q1 2021: $47.02 million | Q2 2021: $47.95 million | Q3 2021: $46.82 million | Q1 2022: $41.02 million | Q2 2022: $39.46 million | Q3 2022: $38.76 million | Q1 2023: $36.36 million | Q2 2023: $37.16 million | Q3 2023: $35.99 million | Q1 2024: $27.49 million | Q2 2024: $26.35 million | Q3 2024: $24.78 million | Q1 2025: $28.66 million | Q2 2025: $27.99 million | Q3 2025: $26.12 million.
- Over the full 16 years of available data (2010 to 2025), CUMBERLAND PHARMACEUTICALS INC's Stockholders Equity has declined by 68.0%.
- Historical annual values: Fiscal year 2025: $24.88 million | Fiscal year 2024: $22.85 million | Fiscal year 2023: $29.60 million | Fiscal year 2022: $36.27 million | Fiscal year 2021: $42.81 million | Fiscal year 2020: $46.99 million | Fiscal year 2019: $51.12 million | Fiscal year 2018: $55.84 million | Fiscal year 2017: $64.12 million | Fiscal year 2016: $73.25 million | Fiscal year 2015: $76.89 million | Fiscal year 2014: $80.76 million | Fiscal year 2013: $79.47 million | Fiscal year 2012: $85.70 million | Fiscal year 2011: $82.93 million | Fiscal year 2010: $77.78 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: